Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by alejo.g3ologiston Apr 26, 2019 11:56am
54 Views
Post# 29675024

RE:RE:RE:the board lots on the ask much higher now

RE:RE:RE:the board lots on the ask much higher now
bigbanktheory wrote: according to some of you, why dump at 0.045 if the boad lots on the ask are so high, supply and demand as some of you have said, this is suppose to go up from what i have learned here, let's see what happens today, gl either way, i'm just following the advice of some of you on this board, 


if you watch the hourly small changes on bid/ask on this stock you are gonna crazy! just let it be, advice to some of you take a break off your screens ..go out for a walk.enjoy the day..or get some work done lol...unless yoy are using your rent money and doing day trading which i would not recommend on this stock... kly will crawl back up eventually(double up easily)...we got the cash(7M) we can pay some debt(Former Talent biotech)..we got good results(trials) so..its just a matter of time!
Longs will be rewarded big time this year!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities